Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

2.

A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.

Nausieda PA, Pfeiffer RF, Tagliati M, Kastenholz KV, DeRoche C, Slevin JT.

Clin Ther. 2005 Jan;27(1):58-63. Erratum in: Clin Ther. 2005 Mar;27(3):360.

PMID:
15763606
3.

A randomized double-blind multi-center trial of hydrogen water for Parkinson's disease: protocol and baseline characteristics.

Yoritaka A, Abe T, Ohtsuka C, Maeda T, Hirayama M, Watanabe H, Saiki H, Oyama G, Fukae J, Shimo Y, Hatano T, Kawajiri S, Okuma Y, Machida Y, Miwa H, Suzuki C, Kazama A, Tomiyama M, Kihara T, Hirasawa M, Shimura H, Hattori N.

BMC Neurol. 2016 May 12;16:66. doi: 10.1186/s12883-016-0589-0. Erratum in: BMC Neurol. 2017 Feb 20;17 (1):35.

4.

Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.

Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A; FIRST-STEP Study Group.

Mov Disord. 2009 Mar 15;24(4):541-50. doi: 10.1002/mds.22343.

PMID:
19058133
5.

Management of Parkinson's disease in Ayurveda: Medicinal plants and adjuvant measures.

Pathak-Gandhi N, Vaidya AD.

J Ethnopharmacol. 2017 Feb 2;197:46-51. doi: 10.1016/j.jep.2016.08.020. Epub 2016 Aug 17. Review.

PMID:
27544001
6.

Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.

Fung VS, Herawati L, Wan Y; Movement Disorder Society of Australia Clinical Research and Trials Group; QUEST-AP Study Group.

Mov Disord. 2009 Jan 15;24(1):25-31. doi: 10.1002/mds.21878.

PMID:
18846551
7.
8.

Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.

Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F.

Mov Disord. 1998 Jan;13(1):39-45.

PMID:
9452324
9.

Effect of antiparkinson drug HP-200 (Mucuna pruriens) on the central monoaminergic neurotransmitters.

Manyam BV, Dhanasekaran M, Hare TA.

Phytother Res. 2004 Feb;18(2):97-101.

PMID:
15022157
10.

Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.

Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.

Int J Clin Pract. 2009 Apr;63(4):613-23. doi: 10.1111/j.1742-1241.2009.02027.x. Epub 2009 Feb 16.

PMID:
19222614
11.

Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group.

Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD, Dubini A, Orlando N, Grimaldi R.

Neurology. 1997 Feb;48(2):363-8.

PMID:
9040722
12.

A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease.

Jankovic J, Hunter C.

Parkinsonism Relat Disord. 2002 Mar;8(4):271-6.

PMID:
12039422
13.

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.

Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C.

Mov Disord. 2013 Nov;28(13):1838-46. doi: 10.1002/mds.25561. Epub 2013 Jul 12.

PMID:
23853029
14.

Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.

Choudhury S, Pradhan R, Paul P, Das M, Gupta A, Ghosh P, Chatterjee S.

Neurol Res. 2014 Sep;36(9):841-6. doi: 10.1179/1743132814Y.0000000339. Epub 2014 Mar 7.

PMID:
24601722
16.

Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.

Katzenschlager R, Evans A, Manson A, Patsalos PN, Ratnaraj N, Watt H, Timmermann L, Van der Giessen R, Lees AJ.

J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1672-7.

17.

Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.

Slevin JT, Fernandez HH, Zadikoff C, Hall C, Eaton S, Dubow J, Chatamra K, Benesh J.

J Parkinsons Dis. 2015;5(1):165-74. doi: 10.3233/JPD-140456.

PMID:
25588353
18.

Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.

Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, Hsu A, O'Connell M, Kell S, Gupta S; APEX-PD Investigators.

Parkinsonism Relat Disord. 2014 Feb;20(2):142-8. doi: 10.1016/j.parkreldis.2013.08.017. Epub 2013 Sep 5.

19.

An open multicenter trial of Sinemet CR in levodopa-naive Parkinson's disease patients.

Olanow CW, Nakano K, Nausieda P, Tetrud JA, Manyam B, Last B, Block G, Liss C, Bush D.

Clin Neuropharmacol. 1991 Jun;14(3):235-40.

PMID:
2070363
20.

Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage.

Parkinson Study Group.

Clin Neuropharmacol. 2007 Mar-Apr;30(2):72-85.

PMID:
17414939

Supplemental Content

Support Center